In a report released today, Joanne Wuensch from Citi maintained a Hold rating on Haemonetics (HAE – Research Report). The company’s shares closed yesterday at $75.05. Discover outperforming ...

In a report released on January 6, Michael Petusky from Barrington maintained a Buy rating on Haemonetics (HAE – Research Report), with a price target of $108.00. The company’s shares closed ...

Haemonetics Co. (NYSE:HAE – Free Report) – Research analysts at Zacks Research cut their Q3 2027 EPS estimates for Haemonetics in a note issued to investors on Wednesday, January 29th.

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Haemonetics Corp. (Symbol: HAE) entered into oversold territory, hitting an RSI reading of ...

Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The company’s portfolio of ...

(RTTNews) - Haemonetics Corporation (HAE), a provider in medical technology focused on advancing patient outcomes, Tuesday announced that it has finalized the sale of its whole blood assets to GVS ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...